OBJECTIVES: Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity. METHODS: Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with human tissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed. RESULTS: Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression. CONCLUSIONS: The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders.
OBJECTIVES:Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity. METHODS: Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with humantissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed. RESULTS:Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression. CONCLUSIONS: The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders.
Authors: C Hallert; C Grännö; S Hultén; G Midhagen; M Ström; H Svensson; T Valdimarsson Journal: Scand J Gastroenterol Date: 2002-01 Impact factor: 2.423
Authors: Eric Marietta; Kay Black; Michael Camilleri; Patricia Krause; Roy S Rogers; Chella David; Mark R Pittelkow; Joseph A Murray Journal: J Clin Invest Date: 2004-10 Impact factor: 14.808
Authors: F Biagi; O Luinetti; J Campanella; C Klersy; C Zambelli; V Villanacci; A Lanzini; G R Corazza Journal: J Clin Pathol Date: 2004-08 Impact factor: 3.411
Authors: Lu Shan; Øyvind Molberg; Isabelle Parrot; Felix Hausch; Ferda Filiz; Gary M Gray; Ludvig M Sollid; Chaitan Khosla Journal: Science Date: 2002-09-27 Impact factor: 47.728
Authors: J L McCarville; J Dong; A Caminero; M Bermudez-Brito; J Jury; J A Murray; S Duboux; M Steinmann; M Delley; M Tangyu; P Langella; A Mercenier; G Bergonzelli; E F Verdu Journal: Appl Environ Microbiol Date: 2017-09-15 Impact factor: 4.792
Authors: Shoko Edogawa; Adam L Edwinson; Stephanie A Peters; Lakshmikanth L Chikkamenahalli; Wendy Sundt; Sara Graves; Sakteesh V Gurunathan; Margaret Breen-Lyles; Stephen Johnson; Roy Dyer; Rondell Graham; Jun Chen; Purna Kashyap; Gianrico Farrugia; Madhusudan Grover Journal: Gut Date: 2019-03-28 Impact factor: 23.059
Authors: Stephen Vanner; Beverley Greenwood-Van Meerveld; Gary Mawe; Terez Shea-Donohue; Elena F Verdu; Jackie Wood; David Grundy Journal: Gastroenterology Date: 2016-02-18 Impact factor: 22.682
Authors: Rebeca Martín; Florian Chain; Sylvie Miquel; Jane M Natividad; Harry Sokol; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán Journal: Hum Vaccin Immunother Date: 2014-04-14 Impact factor: 3.452
Authors: Heather J Galipeau; Justin L McCarville; Sina Huebener; Owen Litwin; Marlies Meisel; Bana Jabri; Yolanda Sanz; Joseph A Murray; Manel Jordana; Armin Alaedini; Fernando G Chirdo; Elena F Verdu Journal: Am J Pathol Date: 2015-10-09 Impact factor: 4.307